Patents by Inventor Darren Gibson
Darren Gibson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7902361Abstract: The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein R1 and R5 are each independently H, C(ORj?) or a hydrocarbyl group optionally substituted by one or more R6 groups; R2, R3, and R4 are each independently H, alkyl or alkenyl, each of which may be optionally substituted with one or more R7 groups; R6 and R7 are each independently halogen, NO2, CN, (CH2)mORa, O(CH2)nORb, (CH2)pNRcRd, CF3, COORe, CONRfRg, CORh, SO3H, SO2Ri, SO2NRjRk, (CH2)qNRa?CORg?, Rf?, (CH2)rNRb?SO2Rh?, SO2NRd?Ri?, SO2NRe?(CH2)sORc?, heterocycloalkyl or heteroaryl, wherein said heterocycloalkyl and heteroaryl may be optionally substituted by one or more substituents selected from aralkyl, sulfonyl, Rm and CORn; Rg?, Rh?, Ri? and Rj? are each independently selected from alkyl, aryl, aralkyl and heteroaryl, each of which may be optionally substituted with one or more substituents selected from halogen, OH, NO2, NH2 CF3 and COOH; m, p, q and r are each independently 0, 1, 2 or 3; nType: GrantFiled: April 21, 2006Date of Patent: March 8, 2011Assignee: Cyclacel LimitedInventors: Shudong Wang, Gavin Wood, Kenneth Duncan, Christopher Meades, Darren Gibson, Janice McLachlan, Alex Perry, David Blake, Daniella I. Zheleva, Peter Martin Fischer
-
Publication number: 20100297156Abstract: The invention relates to compounds which are immunomodulatory compounds and, in particular, can induce IL-12 secretion. The invention also relates to compositions containing the compounds, precursors, and prodrugs of these compounds, use of these compounds as adjuvants in combination with vaccines, and use of these compounds for treatment of diseases or conditions relating to infection, atopic disorders, or cancer.Type: ApplicationFiled: December 20, 2007Publication date: November 25, 2010Applicant: INDUSTRIAL RESEARCH LIMITEDInventors: Gary David Ainge, Bryce Malcolm Buddle, Michel Denis, Robyn Louise Wright, Darren Gibson, Ahivali Ashwin Gulab, David Samual Larsen, Gavin Frank Painter, Natalie Anne Parlane
-
Publication number: 20090318446Abstract: The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof. The present invention seeks to provide further substituted heteroaryl-substituted pyrimidine derivatives. More specifically, the invention relates to compounds that have broad therapeutic applications in the treatment of a number of different diseases and/or that are capable of inhibiting one or more protein kinases.Type: ApplicationFiled: January 11, 2006Publication date: December 24, 2009Applicant: Cyclacel LimitedInventors: Peter Martin Fischer, Shudong Wang, Christopher Meades, Matin J.I. Andrews, Darren Gibson, Kenneth Duncan
-
Publication number: 20090137572Abstract: The present invention relates to selected substituted pyrimidines their preparation, pharmaceutical compositions containing them and their use as inhibitors of one or more protein kinases, and hence their use in the treatment of proliferative disorders, viral disorders and/or other disorders.Type: ApplicationFiled: May 26, 2005Publication date: May 28, 2009Inventors: Shudong Wang, Gavin Wood, Kenneth Duncan, Christopher Meades, Darren Gibson, Janice McLachlan, Peter Martin Fischer
-
Publication number: 20080318954Abstract: The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts thereof, wherein: Z1: 1 is N or CH; Z2 and Z3 are each independently N or CR7; R1, R2, R3, R4, R5, R6, and R7 are each independently H, R8, or R9; each R8 is independently a hydrocarbyl group; and each R9 is independently halo, NO2, alkoxy, CN, CF3, S03H, SO2NR10R11, S02R12, NR13R14(CH2)aCOOR15, (CH2)bCONR16R17, (CH2)cCOR18 or (CH2)dOH; a, b, c and d are each independently 0, 1 2 3 or 4; R10-18 are each independently H or alkyl; provided that when R1 and R2 are both H, Z1 is CH; or Z2 is N; or Z1 is CH and Z2 is N; and wherein the compound is other than 4-(4,5-dimethylthiazol-2-yl)-N-(3,4,5trimethoxyphenyl)-2-pyrimidineamine or 4-(5-(2-hydroxyethyl)-4-methylthiazol-2-yl)N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine.Type: ApplicationFiled: February 7, 2005Publication date: December 25, 2008Applicant: Cyclacel LimitedInventors: Kenneth Duncan, Darren Gibson, Shudong Wang, Daniella I. Zheleva, Peter Martin Fischer
-
Publication number: 20070021452Abstract: The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein R1 and R5 are each independently H, C(ORj?) or a hydrocarbyl group optionally substituted by one or more R6 groups; R2, R3, and R4 are each independently H, alkyl or alkenyl, each of which may be optionally substituted with one or more R7 groups; R6 and R7 are each independently halogen, NO2, CN, (CH2)mORa, O(CH2)nORb, (CH2)pNRcRd, CF3, COORe, CONRfRg, CORh, SO3H, SO2Ri, SO2NRjRk, (CH2)qNRa?CORg?, Rf?, (CH2)rNRb?SO2Rh?, SO2NRd?Ri?, SO2NRe?(CH2)sORc?, heterocycloalkyl or heteroaryl, wherein said heterocycloalkyl and heteroaryl may be optionally substituted by one or more substituents selected from aralkyl, sulfonyl, Rm and CORn; Rg?, Rh?, Ri? and Rj? are each independently selected from alkyl, aryl, aralkyl and heteroaryl, each of which may be optionally substituted with one or more substituents selected from halogen, OH, NO2, NH2 CF3 and COOH; m, p, q and r are each independently 0, 1, 2 or 3Type: ApplicationFiled: April 21, 2006Publication date: January 25, 2007Applicant: Cyclacel LimitedInventors: Shudong Wang, Gavin Wood, Kenneth Duncan, Christopher Meades, Darren Gibson, Janice McLachlan, Alex Perry, David Blake, Daniella Zheleva, Peter Fischer
-
Publication number: 20070021419Abstract: The present invention relates to compounds of formula I, or pharmaceutically acceptable salt thereof, wherein: Z is CR10 or N; one of R1 and R2 is selected from (CH2)mR11, (CH2)mR12, (CH2)mNR12R13, (CH2)mOR12, (CH2)mNR13CO(CH2)nR11, (CH2)mNR13COR12, (CH2)mCONR13(CH2)nR11, (CH2)mCONR12R13, (CH2)mCO(CH2)nR11 and (CH2)mCOR12; where m is 0, 1, 2, 3 or 4 and n is 1, 2, 3 or 4; the other of R1 and R2 is H or R11; R3 and R5 are both H; R4 is H or R11; R6is H or (CH2)pR11, where p is 0 or 1; R7, R9 and R10 are each independently H or R11; R8 is selected from H, halogen, NO2, CN, OR13, NR13R14, NHCOR13, CF3, COR13, R13, CONR13R15, SO2NR13R14, SO2R13, NR13SO2R14, OCH2CH2OH, OCH2CH2OMe, morpholine, piperidine, and piperazine; each R11 is independently halogen, NO2, CN, (CH2)qOR13(CH2)rNR13R14, NHCOR13, CF3, COR13, R13, CONR13R14, SO2NR13R14, SO2R13, OR12, NR13SO2R14, OCH2CH2OH, OCH2CH2OMe, NR13SO2R12, (CH2)sNR12R13, morpholine, piperidine or piperazine, where q, r and s are each independently 0, 1, 2, 3 orType: ApplicationFiled: January 25, 2006Publication date: January 25, 2007Applicant: Cyclacel LimitedInventors: Shudong Wang, Janice McLachlan, Darren Gibson, Ashley Causton, Nicholas Turner, Peter Fischer
-
Publication number: 20060241297Abstract: The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein: (A) “a” is a single bond and “b” is a double bond; R1 and R2 are each independently as defined below; R10 is absent; or (B) “a” is a double bond and “b” is a single bond; R1 is oxygen; R2 is as defined below; and R10 is H or alkyl; X is S, O, NH, or NR7; Y is N or CR8; one of Z1, Z2, and Z3 is N or N+Ra and the remainder are each independently CR7; R1, R2, R5 and R6 are each independently R7; R3 and R4 are each independently R8; each R7 is independently H, halogen, NRbRc, ORd or a hydrocarbyl group optionally substituted by one or more R9 groups; each R8 is independently H or (CH2)nR9, where n is 0 or 1; each R9 is independently selected from H, halogen, NO2, CN, Re, NHCORf, CF3, CORg, NRhRi, CONRjRk, SO2NRlRm, SO2Rn, ORp, OCH2CH2ORq, morpholine, piperidine and piperazine; and Ra-q are each independently H or alkyl, wherein said alkyl group is optionally substituted by one or more R9 gType: ApplicationFiled: January 25, 2006Publication date: October 26, 2006Applicant: Cyclacel LimitedInventors: Shudong Wang, Christopher Meades, Darren Gibson, Peter Fischer
-
Publication number: 20050215548Abstract: The present invention relates to the use of bisarylsulfonamide compounds of formula I wherein W is a C1-5 branched or unbranched alkyl group or a C2-5 alkenyl group; n is 0 or 1; R1 is H, a C1-8 branched or unbranched alkyl group, a C2-8 alkenyl group, or an aryl or aralkyl group; Ar1 is a substituted thienyl, furyl, pyrrolyl, imidazothiazolyl, thiazolyl, pyridyl or phenyl group; and Ar2 is a substituted phenyl, indolyl or benzoimidazolyl group; in the preparation of a medicament for treating proliferative disorders. Further aspects of the invention relate to compounds of formula I, pharmaceutical compositions thereof, and an assay for determining binding to HDM2.Type: ApplicationFiled: November 12, 2004Publication date: September 29, 2005Applicant: Cyclacel LimitedInventors: Shudong Wang, Darren Gibson, Kenneth Duncan, Kevin Bailey, Mark Thomas, David MacCallum, Daniella Zheleva, Nicholas Turner, Peter Fischer